FDA shouldn’t fall for latest ruse to derail biosimilars competition

Headlines about the rising cost of healthcare in the United States are a dime a dozen these days. But imagine how much worse off we would be without low-cost generic drugs, which save consumers $3 billion a week. That’s exactly the overpriced nightmare we could face if the Food and Drug Administration (FDA) does not take the right approach in regulating the latest advanced pharmaceutical therapies.

Read the analysis from Duke University’s Fuqua School of Business MBA student, Jessica Stone, at The Hill.